1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AF245C4C70E8C3178525798A006EE211
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/AF245C4C70E8C3178525798A006EE211!OpenDocument
18
19OpenDocument
2018.97.14.85
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Document Excerpt: Medical Science Liaison Services Excellence: Emerging Trends and Mitigating Risks

DB Image

ID: MD-291


Features:

Metrics, Graphics


Pages/Slides: 4


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click
"Download Free Excerpt".


To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5180 "Medical Science Liaison Services Excellence: Emerging Trends and Mitigating Risks."


Industries Profiled:
Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Health Care


Companies Profiled:
Advanced Biohealing; Allergan; Amylin; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cephalon; EndoPharma; Eisai; Gambro; G.E. Healthcare; Genetech; GlaxoSmithKline; Ironwood Pharma; Kadmon Pharma; Laboratorios Esteve; Lantheus Medical Imaging; Metronic; Merck Sharp and Dohme; Novartis; Novo Nordisk; Onyx Pharma; Pfizer; QLT; Quidel; Shire; Takeda; Theravance; UCB

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.